Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFNASDAQ:FWPNASDAQ:MACKNASDAQ:MISTOTCMKTS:QBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AMACKMerrimack Pharmaceuticals$14.72+0.3%$14.68$11.53▼$15.89$213.88M1.43111,833 shs76,084 shsMISTMilestone Pharmaceuticals$1.64+0.6%$1.66$1.33▼$4.49$87.17M1.77318,498 shs29,523 shsQBIOQ BioMed$0.00$0.00$0.00▼$0.02$29K1.72538 shs1,123 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%MACKMerrimack Pharmaceuticals0.00%-0.34%-0.07%+11.21%+18.39%MISTMilestone Pharmaceuticals-6.86%-3.83%+12.41%+16.43%-57.44%QBIOQ BioMed+100.00%+100.00%0.00%-66.67%-98.57%Secret Bull Market Starts in This Unusual Sector (Ad)"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals2.009 of 5 stars3.43.00.00.02.52.50.0QBIOQ BioMedN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AMISTMilestone Pharmaceuticals2.75Moderate Buy$10.75555.49% UpsideQBIOQ BioMedN/AN/AN/AN/ACurrent Analyst RatingsLatest MIST, QBIO, MACK, ADDXF, and FWP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.003/5/2024MISTMilestone PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.002/26/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMISTMilestone Pharmaceuticals$1M87.17N/AN/A$0.50 per share3.28QBIOQ BioMed$280K0.10N/AN/A($0.11) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AFWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AMACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)QBIOQ BioMed-$2.05M-$0.03N/A∞N/AN/AN/AN/A5/26/2024 (Estimated)Latest MIST, QBIO, MACK, ADDXF, and FWP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023MISTMilestone Pharmaceuticals-$0.30-$0.32-$0.02-$0.32N/AN/A3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AFWPForward Pharma A/SN/A18.43N/AMACKMerrimack PharmaceuticalsN/A43.5043.50MISTMilestone Pharmaceuticals2.9710.1110.11QBIOQ BioMedN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AFWPForward Pharma A/S12.57%MACKMerrimack Pharmaceuticals63.97%MISTMilestone Pharmaceuticals86.18%QBIOQ BioMedN/AInsider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AFWPForward Pharma A/S71.47%MACKMerrimack Pharmaceuticals28.87%MISTMilestone Pharmaceuticals10.40%QBIOQ BioMed28.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableMISTMilestone Pharmaceuticals4753.15 million47.62 millionOptionableQBIOQ BioMed3145.10 million104.18 millionNot OptionableMIST, QBIO, MACK, ADDXF, and FWP HeadlinesSourceHeadlineE&Q Master Cordless Gutta Percha Obturator from Meta BioMednews-medical.net - March 24 at 4:19 AMClearside Biomedical Q4 2023 Earnings Previewmsn.com - March 11 at 7:34 PMQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and Datesbenzinga.com - February 24 at 3:23 AMBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimatesmsn.com - February 13 at 1:26 PMBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthmsn.com - January 28 at 11:09 PMQ BioMed Inc QBIOmorningstar.com - November 16 at 1:23 PMBiomedical Sciences PhD Programuwyo.edu - November 13 at 2:32 PMQ&A: How generative AI could help accelerate biomedical researchphys.org - November 6 at 8:46 AMQBIO Q BioMed Inc.seekingalpha.com - August 18 at 4:51 AMQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in Europepharmabiz.com - April 17 at 9:36 AMQ BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder valueproactiveinvestors.com - April 14 at 10:53 AMQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europefinance.yahoo.com - April 14 at 10:53 AMQ BioMed Stock (OTC:QBIO), Quotes and News Summarybenzinga.com - March 3 at 4:23 PMQ BioMed gets notice of allowable US patent for liver cancer treatment Uttroside Bproactiveinvestors.com - February 10 at 3:27 PMQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Officefinance.yahoo.com - February 10 at 8:27 AMShort Volatility Alert: Q Biomed Incbenzinga.com - January 12 at 2:36 PMQ BioMed Inc. (QBIO)finance.yahoo.com - January 1 at 5:15 PMQ BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Researchproactiveinvestors.com - November 14 at 2:22 PMQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.finance.yahoo.com - November 14 at 9:20 AMQ BIOMED PROVIDES SHAREHOLDER UPDATEprnewswire.com - October 11 at 8:38 AMQ Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatmentproactiveinvestors.com - September 27 at 1:02 PMQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERfinance.yahoo.com - September 27 at 1:02 PMTraders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.finance.yahoo.com - August 25 at 10:16 AMWhat to Expect at BIOMEDevice Bostonmddionline.com - August 10 at 3:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsAll Headlines Company DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Milestone PharmaceuticalsNASDAQ:MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Q BioMedOTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.